Share on StockTwits

Antares Pharma (NASDAQ:ATRS) Director Marvin Samson acquired 25,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 11th. The shares were purchased at an average cost of $2.00 per share, with a total value of $50,000.00. Following the transaction, the director now directly owns 52,778 shares of the company’s stock, valued at approximately $105,556. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Antares Pharma (NASDAQ:ATRS) traded down 1.51% during mid-day trading on Tuesday, hitting $1.96. 480,910 shares of the company’s stock traded hands. Antares Pharma has a 52 week low of $1.87 and a 52 week high of $5.15. The stock’s 50-day moving average is $2.36 and its 200-day moving average is $3.30. The company’s market cap is $255.7 million.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.07) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.07). The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.43 million. Analysts expect that Antares Pharma will post $-0.24 EPS for the current fiscal year.

Antares Pharma, Inc (NASDAQ:ATRS) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products.

Receive News & Ratings for Antares Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.